Occult Positive Axillary Nodes in Breast Cancer Don't Worsen Survival

This article originally appeared here.
Share this content:
Occult Positive Axillary Nodes in Breast CA Don't Worsen Survival
Occult Positive Axillary Nodes in Breast CA Don't Worsen Survival

(HealthDay News) – Occult axillary lymph node metastases do not appear to affect overall or recurrence-free survival in patients with early-stage breast cancer, according to research published in the March 15 issue of Cancer.

Yun Wu, MD, PhD, of the University of Texas M.D. Anderson Cancer Center in Houston, and colleagues conducted a study involving 267 patients with early-stage breast cancer who had undergone axillary lymph node dissection (ALND) and were classified as being lymph node negative using routine pathologic evaluation, and who, consequently, did not receive systemic chemotherapy or hormone therapy. Samples were re-evaluated using a more sensitive pathologic method involving serial sectioning with hematoxylin and eosin staining plus immunohistochemical staining to detect occult axillary lymph node metastases.

The researchers note that, using the enhanced detection methods, 15% who had been classified as lymph node negative on routine evaluation were found to have occult axillary lymph node metastases. Of these, 20% were macrometastases, 40% were micrometastases, and 40% consisted of isolated tumor cells. However, neither the presence nor size of occult metastases appeared to affect overall or recurrence-free survival in this patient population.

"In summary, for the current study, we reviewed a cohort of patients with early-stage breast cancer who had ALND specimens that were lymph node negative on initial evaluation and did not receive systemic therapy. Enhanced pathologic processing identified occult axillary lymph node metastases in a small subset of those patients (15%. Although these patients did not receive systemic chemotherapy or hormone therapy, there were very low recurrence rates in both the occult lymph node metastasis group and in the group without occult metastasis," the authors write.

Abstract

Full Text (subscription or payment may be required)

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs